Stapokibart

ApprovedBiologic

CChengdu Kangnuoxing Biopharma,Inc.

Stapokibart is one of 172 biologic programs targeting Bullous Pemphigoid. It is currently in Approved.

Indications

Total Trials

Active Trials

171

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bullous PemphigoidActive, not recruiting

Non-Allergic RhinitisActive, not recruiting

AmyloidosisActive, not recruiting

Allergic RhinitisActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Prurigo NodularisActive, not recruiting

Seasonal Allergic RhinitisNot yet recruiting

Bullous PemphigoidPhase 3

Active, not recruiting

Non-Allergic RhinitisPreclinical

Active, not recruiting

AmyloidosisPreclinical

Active, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsApproved

Active, not recruiting

Prurigo NodularisPhase 3

Active, not recruiting

Seasonal Allergic RhinitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Stapokibart

CChengdu Kangnuoxing Biopharma,Inc.

Approved

1 3

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 4

Active Comparator

Moderna

Phase 3

1 5

GW685698X

GSK

Phase 3

5 6

Asmanex HFA

Sumitomo Pharma America, Inc.

Phase 3

1 7

Asmanex

Novartis

Preclinical

12 8

Product CM9241GRU

AAche Laboratorios Farmaceuticos S.A.

Phase 3

1 9

Veramyst

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Prurigo Nodularis

NCT06424470

Q4 2026

Phase 3Not yet recruiting

Seasonal Allergic Rhinitis

NCT07678931

N/ANot yet recruiting

Amyloidosis

NCT07143864

Q1 2027

N/ANot yet recruiting

Non-Allergic Rhinitis

NCT07240376

Q1 2028

Not yet recruiting

Seasonal Allergic Rhinitis

NCT07459556

Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT07483268

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.··NCT07459556·400 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·Phase 3·NCT07678931·136 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Not yet recruiting·—·Phase 4·NCT06801353·90 enrolled

A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) .

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.··NCT07483268·600 enrolled

Amyloidosis1 trial

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

Not yet recruiting·FFirst Affiliated Hospital of Chongqing Medical University·N/A·NCT07143864·40 enrolled

Prurigo Nodularis1 trial

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Active, not recruiting·KKeymed Biosciences Co.Ltd·Phase 3·NCT06424470·200 enrolled

Allergic Rhinitis1 trial

Study of Stapokibart Injection in Patients With Allergic Rhinitis

Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06525597·120 enrolled

2 more indications

Non-Allergic Rhinitis1 trial

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

Not yet recruiting·HHuazhong University of Science and Technology·N/A·NCT07240376·90 enrolled

Bullous Pemphigoid1 trial

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·Phase 3·NCT07210554·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Stapokibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stapokibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stapokibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chengdu Kangnuoxing Biopharma,Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: CChengdu Kangnuoxing Biopharma,Inc.

Stapokibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q1 2028

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Chronic Rhinosinusitis With Nasal Polyps2 trials

Amyloidosis1 trial

Prurigo Nodularis1 trial

Allergic Rhinitis1 trial

Non-Allergic Rhinitis1 trial

Bullous Pemphigoid1 trial

References

Drug Info

Quick Facts

Related News